Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Karen Thudium Mueller, Shannon L. Maude(Children's Hospital of Philadelphia), David L. Porter(University of Pennsylvania), Noelle V. Frey(University of Pennsylvania), Patricia A. Wood, Xia Han, Edward Waldron, Abhijit Chakraborty, Rakesh Awasthi, Bruce L. Levine(University of Pennsylvania), J. Joseph Melenhorst(University of Pennsylvania), Stephan A. Grupp(Children's Hospital of Philadelphia), Carl H. June(University of Pennsylvania), Simon F. Lacey(University of Pennsylvania)
Cited by 356Open Access
Abstract
< .0001 for each). CTL019 transgene levels were measurable up to 780 days in peripheral blood. CTL019 trafficking and persistence were observed in bone marrow and cerebrospinal fluid. CTL019 expansion correlated with severity of cytokine release syndrome (CRS) and preinfusion tumor burden in pediatric ALL. The results described here are the first detailed formal presentation of cellular kinetics across 2 diseases and highlight the importance of the application of in vivo cellular kinetic analyses to characterize clinical efficacy and CRS severity associated with CTL019 therapy.
Related Papers
No related papers found
Powered by citation graph analysis